eli lilly glp 1 mounjaro endowment Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value Mounjaro Weight Loss Sales Help

A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

The potent GLP-1 receptor antagonist, exendin-[939] (Ex9), blunted improvements in glucose tolerance in linagliptin-treated control mice and in GcgRAPDX1Cre mice

Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus

Discover the side effects of GLP-1 probiotics, from common gastrointestinal symptoms to serious risks

A major shift is coming to the GLP-1 weight loss drug market in 2026 one that could dramatically change who can access these medications, how theyre taken, and how much they cost.